Cilostazol contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cilostazol}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARM...")
 
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}


==Contraindication==


{|
|<div style="background: WhiteSmoke; float: left; text-align: left; padding: 1em;">
'''''Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. PLETAL is contraindicated in patients with congestive heart failure of any severity.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher =  | date =  | accessdate =  }}</ref>'''''
</div>
|}


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher =  | date =  | accessdate =  }}</ref>
==References==
==References==
{{Reflist}}
{{Reflist}}

Revision as of 04:07, 3 February 2014

Cilostazol
PLETAL® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Studies
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Contraindication

Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. PLETAL is contraindicated in patients with congestive heart failure of any severity.[1]

References

  1. "PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.]".

Adapted from the FDA Package Insert.